My feel is the SP will bounce around on low volume until we move into Phase 3 trials. The base appears to be low 50c with the expectation of two trials built in.
Given the delay in receiving direction of Invex informing the market of how they will proceed, my feeling is that they’re looking to still harmonise both trials, which will mean taking more time to go to the FDA with vision endpoint suggestions.
IXC Price at posting:
61.0¢ Sentiment: Buy Disclosure: Held
